Obermatt
See Similar Stocks →

LENZ Therapeutics

NSQ:LENZ · US52635N1037
PharmaceuticalsSmall

360

11
EV / EBIT100
Price / Owner Earnings50
Owner Earnings Yield1
Dividend Yield1
Price/Sales35
Price/Book57
Return on Capital23
Cash Return on Capital15
Return on Equity21
Profit margins27
Accruals10
Owner Earnings Margin7
Sales growth23
Profit growth22
Reinvestment89
Price momentum1
Debt load95
Refinancing18
Debt Payback1
Liquidity34
Analyst ratings59
Expectations trend36
Market mood81
Value Creation4/20not creating value
  • Creates more value than its capital costs
  • Owner earnings growing
  • Owner earnings per share growing
  • Reinvests at strong returns
  • Solid earnings base

What this means

LENZ Therapeutics doesn't consistently earn more than its cost of capital, so it isn't yet creating shareholder value.

Profile

CountryUSA
IndustryPharmaceuticals
SizeSmall
TypePublic Company
ExchangeNASDAQGS
Employees152
Websitelenz-tx.com
ISINUS52635N1037
Last UpdateApr 2, 2026
Indices
NASDAQ (USA)
Themes
OphthalmologyHealth CareMedicalPharmaceuticalTherapeutics

Description

Lenz Therapeutics, Inc. is a commercial pharmaceutical company focused on the development and commercialization of innovative therapies to improve vision. On July 31, 2025, the U.S.A Food and Drug Administration (FDA) approved VIZZ (aceclidine ophth…

Analysis

Weak and unloved

LENZ Therapeutics, Inc. scores below average on quality and is priced accordingly, a low-conviction position in either direction.

Valuation data is not available for this company.

Growth is tepid; the safety picture is adequate. The company scores 4/20 on our value-creation score: not creating value.

No flags apply to this company at this time: accounts, balance sheet, and cash quality all pass. A clean bill of health is meaningful, not just the absence of a warning. This analysis describes numbers; it is not investment advice.

360° rank · history

1007550250
23
2026

All-time high

73

Mar 2026

All-time low

23

Jun 2026

Average rank

48

across all years

Detailed & Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history.

Current202520242023
Price/Sales
35
—
—
—
Price/Earnings
56
—
—
—
Price/Book
57
—
—
—
Dividend Yield
1
—
—
—
Value (overall)
34
—
—
—

Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.

Similar Stocks

The companies this stock is ranked against.

Compare LENZ Therapeutics with its peers
Trevi Therapeutics
NMQ:TRVI
96
CountryUSA
IndustryPharmaceuticals
SizeSmall
Full Stock Analysis →
EyePoint
NMQ:EYPT
34
CountryUSA
IndustryPharmaceuticals
SizeSmall
Full Stock Analysis →
Milestone Pharmaceuticals
NSQ:MIST
4
CountryCanada
IndustryPharmaceuticals
SizeSmall
Full Stock Analysis →
Pliant Therapeutics
NSQ:PLRX
41
CountryUSA
IndustryPharmaceuticals
SizeSmall
Full Stock Analysis →
LB Pharmaceuticals
NMQ:LBRX
79
CountryUSA
IndustryPharmaceuticals
SizeSmall
Full Stock Analysis →
CalciMedica
NAQ:CALC
—
CountryUSA
IndustryPharmaceuticals
SizeX-Small
Full Stock Analysis →

Make Sense of the Ranks

Every rank runs 1–100 against true peers. Higher is always better.

360° View
1 · Watch OutGood· 100
Value
1 · ExpensiveGood Value· 100
Quality
1 · Weak FundamentalsHigh Quality· 100
Growth
1 · Tough TimesHigh Growth· 100
Safety
1 · High LeverageWell-Financed· 100
Sentiment
1 · SkepticismPositive· 100
Learn More →